A phase II study of rituximab combined with pirarubicincyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 247-253

  Tsurumi, Hisashi ^a   Hara, Takeshi ^a   Goto, Naoe ^a   Kitagawa, Jun Ichi ^a   Kanemura, Nobuhiro ^a   Yoshikawa, Takeshi ^a   Kasahara, Senji ^a   Goto, Hideko ^b   Fukuno, Kenji ^c   Yamada, Toshiki ^d   Sawada, Michio ^c   Shimizu, Masahito ^a   Takahashi, Takeshi ^d   Takami, Tsuyoshi ^e   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kisogawa Municipal Hospital   (Japan)

^c Gifu Red Cross Hospital   (Japan)

^d Gifu Municipal Hospital   (Japan)

^e GIFU UNIVERSITY   (Japan)

Author keywords

Follicular lymphoma; Indolent lymphoma; Non Hodgkin lymphoma; Pirarubicin; R CHOP; R THP COP

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PIRARUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL EFFECTIVENESS; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HEMATURIA; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG TOXICITY; LYMPHOCYTOMA; LYMPHOPLASMACYTIC LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SPLENIC MARGINAL ZONE LYMPHOMA; STOMATITIS; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; VINCRISTINE;

EID: 84862959131     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.606383     Document Type: Article

References (41)

1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311: 1471-1475. (Pubitemid 15211022)
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
3. Fisher RI, Shah P. Current trends in large cell lymphoma. Leukemia 2003;17:1948-1960. (Pubitemid 37322124)
4. Pfreundschuh M, Schubert J, Ziepert M, et al.; German High- Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732. (Pubitemid 41742196)
6. Umezawa H, Takahashi Y, Kinoshita M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 1979;32: 1082-1084. (Pubitemid 10071255)
7. Takagi T, Oguro M. (20-R)-49-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 1987;20:151-154. (Pubitemid 17152003)
8. Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994;22:261-268. (Pubitemid 2037590)
9. Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 1990;13(Suppl. 1):S15-S19.
10. Niitsu N, Umeda M. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non- Hodgkin's lymphoma in elderly patients: a prospective study. Leukemia 1997;11:1817-1820. (Pubitemid 27485124)
11. Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non- Hodgkin's lymphoma. Int J Hematol 2005;81:246-254. (Pubitemid 41364491)
12. Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 2004;130:107-113. (Pubitemid 38316674)
13. Tsurumi H, Hara T, Goto N, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007;25:107-114. (Pubitemid 47507877)
14. Hara T, Tsurumi H, Goto N, et al. Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol 2010;136:65-70.
15. Kasahara S, Hara T, Tsurumi H, et al. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011;52:629-634.
16. Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology & genetics: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 109-236.
17. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31: 1860-1861.
18. Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005;131:73-79. (Pubitemid 40192931)
19. Kitagawa J, Hara T, Tsurumi H, et al. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U). J Cancer Res Clin Oncol 2009;135:53-59.
20. Sawada M, Tsurumi H, Yamada T, et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 2002;68:354-361.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
22. Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987;71:1079-1085. (Pubitemid 18002219)
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
24. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (Pubitemid 39166497)
25. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-5026. (Pubitemid 46224008)
26. Apostolidis JH, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000;18:527-536. (Pubitemid 30078534)
27. Aoki S, Tsukada N, Nomoto N, et al. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 1998;17:465-470. (Pubitemid 29083421)
28. Koharazawa H, Kanamori H, Sakai R, et al. Long-term outcome of L86 and L97 protocols for adult acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:2133-2140.
29. Takamatsu Y, Suzumiya J, Utsunomiya A, et al. Kyushu Hematology Organization for Treatment Study Group (K-HOT). THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol 2010;84:391-397.
30. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 2005;23:1088-1095. (Pubitemid 46202263)
31. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 3 4 schedule. Blood 2004;103:4416-4423. (Pubitemid 38745964)
32. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-1614.
33. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
34. Delaloye AB, Antonescu C, Louton T, et al. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med 2009;50:1837-1843.
35. Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of shortcourse CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008;14:7088-7094.
36. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108:2540-2544.
37. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521-3529. (Pubitemid 37409366)
38. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704. (Pubitemid 46224168)
39. Sacchi S, Pozzi S, Marcheselli R, et al. Italian Lymphoma Study Group. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007;110:121-128. (Pubitemid 46992032)
40. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/ refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-2812.
41. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-3389.